Wisconsin Alumni Research Foundation

Research Tools
Research Tools
Antibodies to NGAL for Detection of Cancer and Kidney Damage
WARF: P09185US

Inventors: Michael Gould, Jill Haag

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in unique antibodies to neutrophil gelatinase-associated lipocalin (NGAL).
Overview
Neutrophil gelatinase-associated lipocalin (NGAL) is a recently discovered cytokine. Because many types of cells produce NGAL in response to injury, it provides a biomarker for several chronic conditions. NGAL can be used in a diagnostic assay to detect certain types of cancer cells. It serves as a strong indicator of kidney damage, and may be useful to monitor other chronic conditions as well.
The Invention
UW-Madison researchers have developed purified antibodies to NGAL. These unique antibodies can be used in immunoassays for the diagnosis and prognosis of some types of cancer, renal failure and other diseases.
 
Applications
  • Immunoassays for cancer, kidney damage and other chronic conditions
     
Key Benefits
  • Provides unique antibodies against NGAL
Additional Information
For More Information About the Inventors
Publications
  • Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., and Gould M.N. 1998. Heterogeneous Expression of the Lipocalin N-gal in Primary Breast Cancers. Int. J. Cancer 79, 565-572.
For current licensing status, please contact Jennifer Gottwald at [javascript protected email address] or 608-960-9854

WARF